Laser-assisted machining (LAM) of non-monolithic composite bone material

    公开(公告)号:US10729497B2

    公开(公告)日:2020-08-04

    申请号:US16310917

    申请日:2017-06-19

    Abstract: An apparatus and method for laser-assisted machining (LAM) of non-monolithic composite bone material is described. A high intensity focused laser beam conducts bone material removal in extremely short time duration without causing any thermal (necrosis) and mechanical damage to the material surrounding the bone-laser interaction region. A computer associated with the apparatus for machining bone preferably employs a Multiphysics computational modeling approach which takes into account physical phenomena such as heat transfer, fluid flow, convection mixing, and surface tension when determining bone target volume, calculating material properties of the multicomponent and multicomposition composite bone material, determining parameters for the laser-assisted machining based on the material properties, and performing the laser-assisted cutting/shaping/machining of bone.

    METHODS FOR ENGINEERING PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING MYB TRANSCRIPTION FACTORS

    公开(公告)号:US20200181632A1

    公开(公告)日:2020-06-11

    申请号:US16476895

    申请日:2018-01-17

    Abstract: The amount of proanthocyanidins (PAs) found in cells of plants can be engineered or adjusted through regulation of transcription factors that affect PA biosynthesis. Increasing expression of genes encoding TT2-type MYB transcription factors, including homologs of AtTT2 of Arabidopsis thaliana such as GHMYB36 or GHMYB IO of cotton plants or GmTT2A or GmTT2B of soybean plants, leads to increased PA content. Expression of these genes can be increased through any suitable methods, including mutation of the genes and transformation of plant cells to include exogenous genes resulting in increased expression.

    Blood Test for Screening Out Amyloid and Alzheimers Disease Presence

    公开(公告)号:US20190234967A1

    公开(公告)日:2019-08-01

    申请号:US16312346

    申请日:2017-06-22

    Inventor: Sid E. O'Bryant

    Abstract: The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

Patent Agency Ranking